Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  Users Online: 746 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

 Table of Contents  
Year : 2018  |  Volume : 8  |  Issue : 4  |  Page : 203  

Chondroitinase ABC enzyme: A potential treatment option for spinal cord injury

Department of Pharmacology, Adesh Institute of Medical Sciences and Research, Bathinda, Punjab, India

Date of Web Publication20-Nov-2018

Correspondence Address:
Dr. Rajiv Mahajan
Department of Pharmacology, Adesh Institute of Medical Sciences and Research, Bathinda - 151 101, Punjab
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ijabmr.IJABMR_336_18

Rights and Permissions

How to cite this article:
Mahajan R. Chondroitinase ABC enzyme: A potential treatment option for spinal cord injury. Int J App Basic Med Res 2018;8:203

How to cite this URL:
Mahajan R. Chondroitinase ABC enzyme: A potential treatment option for spinal cord injury. Int J App Basic Med Res [serial online] 2018 [cited 2022 Jan 20];8:203. Available from: https://www.ijabmr.org/text.asp?2018/8/4/203/245811

After spinal cord injury (SCI), axons fail to regenerate in the adult mammalian central nervous system (CNS) leading to permanent paralysis.[1] At the site of injury, glial reaction occurs resulting in the formation of glial scar. Glial reaction results in recruitment of microglia, oligodendrocytes precursors, meningeal cells, astrocytes, and stem cells, besides containing oligodendrocytes and myelin debris. Most of these cells release molecules, inhibitory to axon regeneration, resulting in failure of regeneration. Even remyelination may be unsuccessful in such an environment.[2] Glial scar also contains chondroitin sulfate proteoglycan (CSPG), which along with inflammation, is recovery inhibiting factor.[3]

Treatment strategy targeting CSPG using chondroitinase ABC (ChABC) enzyme offers the opportunity to improve the outcome of SCI. ChABC is obtained from Proteus vulgaris and it acts by degrading the glycosaminoglycan side chains of CSPGs.[4] Degradation of CSPG with the use of ChABC removes a regeneration inhibition from the glial scar. The plasticity in the CNS is increased with the removal of perineural nets. The mechanism of action of ChABC is unique and does not overlap with mechanisms of other available treatment options for SCI, thus making ChABC an attractive option for the treatment of SCI in combination with other strategies.[5]

Treatment with ChABC has shown promising results in animal models of SCI. In a study in male Wistar rats using combination of low-level laser therapy (LLLT) as anti-inflammatory agent and ChABC as CSPG digesting factor after inducing SCI by “clip compression,” combination of LLLT and ChABC showed more effect on reduction of cavity size, improvement of myelination and number of axons around the cavity and decreasing the expression of glycogen synthase kinase-3 β, CSPG and aquaporin 4 expression compared to LLLT and ChABC alone, resulting in more functional recovery in combination group.[3] In another experiment, ChABC treatment reinstated postsynaptic activity below the lesion as evident to electrical stimulation of corticospinal neurons and promoted functional recovery of locomotor and proprioceptive behaviors in rats.[1] ChABC has also shown to promote functional recovery in acute SCI in rats when used in combination with rehabilitation, even after 4 weeks of spinal injury.[6]

In a recently concluded study with dog models of naturally occurring severe chronic spinal cord injuries, intraspinal injections of ChABC have shown favorable results and authors have recommended to start human trials.[7]

Although no human trials have been conducted till date, the results in animal studies are promising and points toward the potential benefit of ChABC in SCI.

   References Top

Bradbury EJ, Moon LD, Popat RJ, King VR, Bennett GS, Patel PN, et al. Chondroitinase ABC promotes functional recovery after spinal cord injury. Nature 2002;416:636-40.  Back to cited text no. 1
Fawcett JW, Asher RA. The glial scar and central nervous system repair. Brain Res Bull 1999;49:377-91.  Back to cited text no. 2
Janzadeh A, Sarveazad A, Yousefifard M, Dameni S, Samani FS, Mokhtarian K, et al. Combine effect of chondroitinase ABC and low level laser (660nm) on spinal cord injury model in adult male rats. Neuropeptides 2017;65:90-9.  Back to cited text no. 3
Raspa A, Bolla E, Cuscona C, Gelain F. Feasible stabilization of chondroitinase abc enables reduced astrogliosis in a chronic model of spinal cord injury. CNS Neurosci Ther 2018. [Epub ahead of print]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29855151. [Last accessed 28 Sep 2018].  Back to cited text no. 4
Zhao RR, Fawcett JW. Combination treatment with chondroitinase ABC in spinal cord injury – Breaking the barrier. Neurosci Bull 2013;29:477-83.  Back to cited text no. 5
Wang D, Ichiyama RM, Zhao R, Andrews MR, Fawcett JW. Chondroitinase combined with rehabilitation promotes recovery of forelimb function in rats with chronic spinal cord injury. J Neurosci 2011;31:9332-44.  Back to cited text no. 6
Hu HZ, Granger N, Pai SB, Bellamkonda RV, Jeffery ND. Therapeutic efficacy of microtube-embedded chondroitinase ABC in a canine clinical model of spinal cord injury. Brain 2018;141:1017-27.  Back to cited text no. 7


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  In this article

 Article Access Statistics
    PDF Downloaded249    
    Comments [Add]    

Recommend this journal